



HOMES AND SENIORS SERVICES

POLICY & PROCEDURE NUMBER: 2.4

DEPARTMENT: *Infection Control* **SUBJECT:** *Immunization –Residents Influenza, Pneumovax, Antiviral and COVID-19*

APPROVAL DATE: April 2004

REVISION DATE: April 2007; March 2016

REVIEW DATE: March 2017; Dec. 2019
2020; June 2021; Nov. 2022

REVISION DATE: November 2018; Dec.

Page 1 of 4

PURPOSE:

Elgin County Homes will provide influenza/pneumovax, and COVID-19 vaccination to eligible residents, as per the Canadian Immunization Guide and Ministry of Health and Long-Term Care direction.

The Professional Advisory Committee (PAC), including Pharmacist, Public Health, Medical Director and Manager of Resident Care, and IPAC program manager will develop and keep up-to-date-vaccination protocols within the Homes.

PROCEDURE:

INFLUENZA VACCINATION:

1. All eligible residents will be offered influenza vaccine, except as contraindicated or otherwise ordered by the attending physician. The attending physician may delegate the authority to registered staff through the annual signed “Medical Directive for Administration of the Influenza Vaccine for County of Elgin Homes Residents” (IC – Form 2.4a). Registered staff may administer the influenza vaccine to eligible residents according to manufacturer’s instructions after performing a health assessment, reviewing contraindications and receiving informed consent (IC – Form 2.4b).
2. An influenza vaccine “Flu fact sheet” will be provided to the resident and informed consent will be obtained annually for influenza vaccination. When the resident is not competent to sign an informed consent, the substitute decision maker will be contacted to provide informed consent.
3. A physician’s order for “influenza vaccine (or designated name)” will be obtained prior to administration.
4. Adrenaline 1 ml. (1:1000) I.U.) ampoule will be available as per medical directive and Management of Fainting and Anaphylactic Reaction policy 2.6 on the injection tray, to be used in case of adverse reaction. Registered staff to check Medical Directives for adrenaline dosage.



HOMES AND SENIORS SERVICES

POLICY & PROCEDURE NUMBER: 2.4

DEPARTMENT: *Infection Control* **SUBJECT:** *Immunization –Residents Influenza, Pneumovax, Antiviral and COVID-19*

APPROVAL DATE: April 2004

REVISION DATE: April 2007; March 2016

REVIEW DATE: March 2017; Dec. 2019
2020; June 2021; Nov. 2022

REVISION DATE: November 2018; Dec.

Page 2 of 4

5. Vaccine name, Lot #, expiry date, dose, route, site and date/time of the influenza vaccination will be recorded in the resident's eMAR

PNEUMOVAX:

1. A pneumovax vaccine will be offered as per medical directive to all eligible residents who have not received a pneumovax vaccine unless contraindicated.
2. A pneumovax vaccine fact sheet will be provided to the resident and informed consent for pneumovax will be obtained. When the resident is not competent to sign and provide informed consent, the substitute decision maker will be contacted to provide informed consent (IC – Form 2.4b).
3. A physician's order for "Pneumovax Vaccine 0.5ml. I.M. or S.C." will be obtained
4. Adrenaline 1 ml. (1:1000) ampoule will be available as per medical directive and Management of Fainting and Anaphylactic Reaction policy 2.6 to be used in case of adverse reaction. Registered staff to check Medical Directives for adrenaline dosage.

COVID-19:

Effective June 2021, two (2) authorized Registered Nurses/Home will have the authority to offer COVID-19 Vaccine to eligible residents within the parameters of the County of Elgin Homes Medical Directive for COVID-19 Vaccine for Residents – 2.4d.

COVID-19 Vaccination will be offered (as per medical directive) to all eligible residents who have not received COVID-19 vaccine (unless contraindicated). Homes have the authority to offer all eligible residents within the parameters of the County of Elgin Homes Medical Directive for COVID-19 Vaccine for Residents – 2.4d.

Residents will be offered:

Primary series: two (2) dose schedule of COVID-19 vaccination (interval between based on Canadian Immunization Guide or current). OR, based on Canadian Immunization Guide,



HOMES AND SENIORS SERVICES

POLICY & PROCEDURE NUMBER: 2.4

DEPARTMENT: *Infection Control* **SUBJECT:** *Immunization –Residents Influenza, Pneumovax, Antiviral and COVID-19*

APPROVAL DATE: April 2004

REVISION DATE: April 2007; March 2016

REVIEW DATE: March 2017; Dec. 2019

REVISION DATE: November 2018; Dec.

2020; June 2021; Nov. 2022

Page 3 of 4

moderately to severely immunocompromised individuals, the primary series includes one additional dose that is not referred to as a booster dose.

Booster doses of an authorised COVID-19 vaccine at intervals specified by National Advisory Committee on Immunization and Canadian Immunization Guide (e.g. bivalent vaccination)

1. A COVID-19 fact sheet will be provided to the resident and informed consent for each dose of COVID-19 will be obtained. When the resident is not competent to sign and provide informed consent, the substitute decision maker will be contacted to provide informed consent.
2. Adrenaline 1 ml. (1:1000) ampoule will be available as per medical directive and Management of Fainting and Anaphylactic Reaction policy 2.6 to be used in case of adverse reaction. Registered staff to check Medical Directives for adrenaline dosage.

ANTIVIRAL:

Example: Tamiflu

1. Antiviral therapy may be recommended by the Medical Officer of Health to be given to the residents of long-term care homes during a confirmed influenza outbreak.
2. Annually, prior to flu season, the resident/substitute decision maker will be asked to provide informed consent for antiviral medication.
3. The Home will provide pharmacy with any information required (age, weight, lab results) to assess individual resident dosing for antiviral medication.
4. The pharmacist will provide individual resident dosing for antiviral medications.
5. See “Elgin County Homes and Seniors Services Consent Form – Influenza and Pneumococcal Vaccine and Antiviral Therapy (1C – Form 2.4b).



HOMES AND SENIORS SERVICES

POLICY & PROCEDURE NUMBER: 2.4

DEPARTMENT: *Infection Control* **SUBJECT:** *Immunization –Residents Influenza, Pneumovax, Antiviral and COVID-19*

APPROVAL DATE: April 2004

REVISION DATE: April 2007; March 2016

REVIEW DATE: March 2017; Dec. 2019
2020; June 2021; Nov. 2022

REVISION DATE: November 2018; Dec.

Page 4 of 4

Example: Paxlovid:

1. All residents will be assessed annually (or with any significant change in health status) using the Ontario Covid Treatment Screener.
2. All resident at risk of serious illness based on health, age and vaccination status, plus an assessment from a health care provider will be offered antiviral medication, as ordered by the attending physician.
3. Paxlovid must be taken within 5 days of the start of symptoms to be effective.
4. The Home will provide pharmacy with any information required (age, weight, lab results) to assess individual resident dosing for antiviral medication.
5. A list of all medications the resident is currently taking will be assessed by pharmacy for contraindications prior to initiating treatment.
6. Consent will be obtained by the resident/substitute decision maker annually for Paxlovid.

References:

Public Health Ontario; Medical Officer of Health; Provincial Infectious Diseases Advisory Committee (PIDAC),

PFIZER COVID-19 product monograph

Moderna COVID 19 Product Monograph

Ministry of Health COVID Resources

County of Elgin Homes Medical Directive for COVID-19 Vaccine for Residents

County of Elgin Homes Infection Prevention and Control policy 2.6 Management of Fainting and Anaphylactic Reactions

<https://www.ontario.ca/covid-treatment-screener>

<https://www.ontariohealth.ca/sites/ontariohealth/files/2022-04/Paxlovid-PatientFactSheet.pdf>

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI); October 7, 2022